Cevidoplenib
Tier C — Watch / tradeCevidoplenib
Targets:Syk
Indications (approved):Immune thrombocytopenic purpura, Rheumatoid arthritis
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| SKI-O-703-001 | 3934-20-1Available | 2,4-dichloropyrimidine |
| SKI-O-703-002 | 112758-40-4 | 3-methyl-1H-pyrazole-4-carbaldehyde |
| SKI-O-703-003 | 1448307-66-1 | 1-(2-chloropyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde |
| SKI-O-703-004 | 1703788-55-9 | (5-amino-1-methyl-1H-indol-3-yl)(cyclopropyl)methanone |
| SKI-O-703-005 | 1703788-56-0 | 1-(2-((3-(cyclopropanecarbonyl)-1-methyl-1H-indol-5-yl)amino)pyrimidin-4-yl)-3-methyl-1H-pyrazole-4-carbaldehyde |
| SKI-O-703-006 | 338464-55-4 | (S)-isoxazolidin-4-ol hydrochloride |
Frequently asked questions
What are the approved indications of Cevidoplenib?
Approved indications include: Immune thrombocytopenic purpura, Rheumatoid arthritis.
When does the Cevidoplenib patent expire?
No public expiry year is available for Cevidoplenib yet; this page updates once verified.
How many synthesis routes are recorded for Cevidoplenib?
1 synthesis routes are recorded; the shortest is 3 steps with 270 mg (SKI-O-703) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Cevidoplenib intermediates?
1 intermediate CAS of Cevidoplenib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Cevidoplenib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08